{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:57:50Z","timestamp":1793642270505,"version":"4.5.1"},"reference-count":33,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2005,4,5]],"date-time":"2005-04-05T00:00:00Z","timestamp":1112659200000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Headache"],"published-print":{"date-parts":[[2005,4]]},"abstract":"<jats:p>Background.\u2014More than 50% of migraine sufferers rely on over\u2010the\u2010counter medications for the treatment of migraine. Along with other over\u2010the\u2010counter products, aspirin is considered by the US Headache Consortium to be an option for first\u2010line migraine treatment. This study assessed the efficacy and tolerability of aspirin versus placebo for the acute treatment of a single acute attack of migraine.<\/jats:p>\n                  <jats:p>Methods.\u2014This prospective, randomized, double\u2010blind, parallel\u2010group, placebo\u2010controlled study evaluated the efficacy of a single, 1000\u2010mg dose of aspirin for the treatment of acute moderate to severe migraine, with or without aura. Subjects recorded all study evaluations in a diary at baseline and at .5, 1, 2, 3, 4, 5, 6, and 24 hours after treatment. Pain was rated on a 4\u2010point ordinal scale from no pain to severe pain. The primary efficacy end point was headache response at 2 hours. Secondary efficacy parameters included reduction of nausea, photophobia and phonophobia, pain intensity difference, and headache recurrence at 24 hours.<\/jats:p>\n                  <jats:p>\n                    Results.\u2014Of 485 subjects enrolled, 409 took study medication and 401 treated a confirmed migraine attack (201 with aspirin and 200 with placebo). Baseline demographic and migraine characteristics were not significantly different between groups. The 2\u2010hour headache response rate was 52% with aspirin versus 34% with placebo (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; .001). Aspirin was significantly more effective than placebo for pain reduction beginning 1 hour after dosing (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; .001) and continuing throughout the 6\u2010hour evaluation period. Significantly (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; .05), more subjects were pain free from the 1\u2010hour evaluation through the 6\u2010hour evaluation. Of the aspirin\u2010treated subjects, 20% were pain free at 2 hours versus only 6% of placebo\u2010treated subjects. At 24 hours, the headache recurrence rate was 21.8% for aspirin (23 of 105 subjects) and 27.7% for placebo (19 of 68 subjects). Only 34% of aspirin\u2010treated subjects needed rescue medication at 24 hours compared with 52% of placebo\u2010treated subjects (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; .001). Aspirin was well tolerated, and adverse events were not significantly different between groups.\n                  <\/jats:p>\n                  <jats:p>Conclusions.\u2014This study demonstrates that aspirin is safe and effective for treatment of acute migraine in appropriately selected patients.<\/jats:p>","DOI":"10.1111\/j.1526-4610.2005.05065.x","type":"journal-article","created":{"date-parts":[[2005,4,5]],"date-time":"2005-04-05T08:52:40Z","timestamp":1112691160000},"page":"283-292","source":"Crossref","is-referenced-by-count":66,"title":["Aspirin Is Efficacious for the Treatment of Acute Migraine"],"prefix":"10.1111","volume":"45","author":[{"given":"Richard B.","family":"Lipton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Baggish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto R.","family":"Yataco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James V.","family":"Sorrentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John N.","family":"Quiring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,4,5]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra010917"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2001.041007646.x"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2003.03067.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2001.041007638.x"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1998.3802087.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1992.03480010072027"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06711-3"},{"key":"e_1_2_7_9_2","first-page":"10","article-title":"Pharmacy Times OTC recommendation survey: why it matters","author":"Anonymous","year":"2003","journal-title":"Pharmacy Times"},{"key":"e_1_2_7_10_2","unstructured":"MatcharDB YoungWB RosenbergJH et al.Evidence\u2010based guidelines for migraine headache in the primary care setting: pharmacological management of acute attacks.2000. Available at:http:\/\/www.aan.com\/professionals\/practice\/pdfs\/gl0087.pdf. Accessed May 18 2004."},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.6.754"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1987.hed2702090.x"},{"issue":"1","key":"e_1_2_7_13_2","first-page":"40","article-title":"Aspirin is efficacious for treatment of severe pain associated with tension headache [abstract]","volume":"2","author":"MacEachern L","year":"2001","journal-title":"J Pain"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2001.00216.x"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1995.1506531.x"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)90526-0"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2003.00470.x"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1994.1402156.x"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2004.00783.x"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2000.00101.x"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2002.02076.x"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000079544"},{"issue":"7","key":"e_1_2_7_23_2","first-page":"1","article-title":"Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain","volume":"8","author":"Headache Classification Committee of the International Headache Society","year":"1988","journal-title":"Cephalalgia"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.22.3486"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2000.00055.x"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.55.2.210"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1992.00400180125021"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.20.2599"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2003.00546.x"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2003.00599.x"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1993.1304233.x"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026179517081"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.18.2443"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2003.03042.x"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1526-4610.2005.05065.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1526-4610.2005.05065.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/j.1526-4610.2005.05065.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1526-4610.2005.05065.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T07:46:31Z","timestamp":1762069591000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/j.1526-4610.2005.05065.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["10.1111\/j.1526-4610.2005.05065.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1526-4610.2005.05065.x","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4]]}}}